Together with 9 other partner organisations, Abingdon Health plc is developing a rapid serological diagnostic test to detect Plasmodium vivax hypnozoites, which will be critical for malaria disease control, especially in remote areas. Coordinated by Michael White, Inès Vigan-Womas and Makhtar Niang, the project brings together a consortium of 8 organisations across 7 countries, including diagnostics developers, malaria sero-epidemiologists, and regulatory experts from Africa, Europe, and Australia.
The PvSeroRDT project is tackling one of the most persistent challenges in malaria elimination: the detection of Plasmodium vivax, a parasite capable of lying dormant in the liver and reactivating months after infection. These hidden forms often go undetected by conventional tools, making P. vivax especially difficult to eliminate. The test will be simple, portable and suitable for use in the field.
Abingdon Health is a global specialist in rapid diagnostics, leads test development. Our role includes transforming biomarker science into a working, user-friendly test, using nearly 20 years of experience in developing lateral flow tests across health and other sectors. Abingdon Health ensures that the test meets high quality standards, following certified development processes, aligned to Good Manufacturing Practice (GMP), with Design For User and Design For Manufacture considerations at the forefront.
πππ² π©π«π¨π£πππ π©π’π₯π₯ππ«π¬ π°π'π«π πππ―ππ§ππ’π§π :
πΉ Rapid diagnostic test development
πΉ Africa-based manufacturing capacity
πΉ Clinical validation across Senegal, Ethiopia & Madagascar
πΉ Regulatory pathway strategy
Michael White, Research Director at Institut Pasteur had this to say:
βWe are so grateful to have Abingdon Health plc as our key partner leading the R&D of the lateral flow test - your expertise will be invaluable for this project! With nearly two decades of experience developing and producing lateral flow diagnostics, and a proven track record of over 200 projects, Abingdon Health brings the technical excellence and regulatory knowledge we need. Their ability to translate scientific innovation into practical, user-friendly tests - combined with their GMP-aligned processes and design-for-manufacture approach - positions them perfectly to help us transform our research into a field-ready solution to support malaria elimination.β
DiaTropix (DTX) will take on manufacturing. This local platform, embedded within the Institut Pasteur de Dakar, is dedicated to making diagnostics more accessible across Africa. DTX already produces CE-marked tests and is scaling up to manufacture new products like PvSeroRDT, with support from multiple global health organisations.
FIND | Pasteur Foundation - UK | Pasteur Foundation | Institut Pasteur de Madagascar I WEHI (Walter and Eliza Hall Institute of Medical Research) I Armauer Hansen Research Institute I London School of Hygiene and Tropical Medicine, U. of London I Pasteur Network
